PD13-08: A Prospective and Longitudinal Cohort Study Assessing Mental Wellbeing in Prostate Cancer: Preliminary Analysis of the MIND-P Study

Oliver Brunckhorst*, Callum James, Jack Fanshawe, Mohamed Hammadeh, London, United Kingdom, Madeleine Williams, Robert Thomas, Bedford, United Kingdom, Shahid Khan, Redhill, United Kingdom, Matin Sheriff, Gillingham, United Kingdom, Hashim Ahmed, Mieke Van Hemelrijck, Robert Stewart, Prokar Dasgupta, Kamran Ahmed, London, United Kingdom

Introduction: Prostate cancer is known to significantly impact patients’ mental wellbeing. Mental health issues such as depression and anxiety, along with related outcomes such as fear of recurrence, body image perception and masculine self-esteem are impacted. Uncertainty remains however regarding patient, oncological and treatment factors associated with poorer mental wellbeing outcomes. This ongoing study therefore aims to explore these during the initial follow up period.

Methods: MIND-P is an ongoing longitudinal and prospective cohort study following patients for 12 months across six sites (NCT04647474). Inclusion criteria were newly diagnosed participants receiving active surveillance (AS), radical prostatectomy (RP) or radiotherapy (RT), or androgen deprivation monotherapy (ADT). Validated mental wellbeing measures were collected 3-monthly including depressive and anxiety symptoms, fear of recurrence, body image perception and masculine self-esteem. Other measures included the FACT-G social wellbeing scale and EPIC-26. One-way ANOVA was used to assess treatment group scores with univariate logistic regression conducted evaluating associative factors against a composite outcome of developing any significant mental wellbeing issue.

Results: Across all sites, 136 participants were recruited (AS= 32, RP= 34, RT= 49 and ADT=21). 78 participants have undergone at least 3 months follow up and were included in the analysis. Overall, 14.1% of participants demonstrated probable depression and 9.0% probable anxiety during follow up. When considering significant levels of any mental wellbeing outcome, 34.6% of participants were affected. Whilst no significant differences were seen between mental wellbeing outcomes and treatment cohorts, younger patients had increased odds of developing a mental wellbeing problem (OR 1.06, p=0.035). Additionally, Black or African ethnicity (OR 6.59, p=0.01) was significant. Baseline higher depressive (OR 1.45, p<0.001) and anxiety symptom scores (OR 1.34, p<0.001) were also associated with poorer wellbeing, with higher social wellbeing scores (OR 0.90, p=0.04) seen to be protective. No other associative demographic or oncological factors were identified in our cohort.

Conclusions: A significant proportion of patients experience mental wellbeing problems. Age and ethnicity appear to be important associative factors for these, along with baseline depressive and anxiety scores. Routine screening, along these factors should be considered to improve quality of life in patients.

Source of Funding: King's Medical Research Trust and The Malcolm Coptcoat Trust